Journal of Internal Medicine · 1990 · 15 citations · 8 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyLipid BiochemistryHypertension PharmacotherapyLipid MetabolismLipid-lowering TherapyAntihypertensive PharmacologyBlood LipidsCaptopril TherapyLipid-lowering Drug EfficacyLow-density Lipoprotein Cholesterol LoweringTriglyceride Lowering
In a 24-week randomized multicentre single-blind study, including mild to moderate hypertensives free from other diseases, the effect on blood lipids of captopril (n = 51) was studied and compared with that of metoprolol (n = 53). In order to keep the diastolic pressure less than 95 mm Hg, bendroflumethiazide was added to the medication for 11 patients in the captopril group and 11 patients in the metoprolol group. Neither captopril nor metoprolol altered total cholesterol significantly. Captopril as monotherapy increased HDL-cholesterol by 6.2% (P less than 0.01) and decreased triglycerides by 10.6% (P less than 0.05). Metoprolol as monotherapy decreased HDL-cholesterol by 5.6% (P less than 0.01) and increased triglycerides by 10.3% (P less than 0.05). When bendroflumethiazide was added the favourable effect of captopril on the blood lipids disappeared while the undesirable effect of metoprolol became more pronounced.
8
Multiple Risk Factor Intervention Trial
Deborah M. Michel · JAMA · 1982 · 1.7K citations
Stanley Peart, Greta Barnes, George Broughton et al. · BMJ · 1985 · 1.5K citations · Full text
EFFECT OF PROPRANOLOL AND PRAZOSIN ON BLOOD LIPIDS
Paul Leren, Anders Helgeland, Ingar Holme et al. · The Lancet · 1980 · 374 citations